NCT00753649View on ClinicalTrials.gov

Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants

PHASE4CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

September 23, 2008

Primary Completion Date

March 12, 2013

Study Completion Date

March 12, 2013

Conditions
Hepatitis BTetanusPoliomyelitisDiphtheriaHaemophilus Influenzae Type bAcellular Pertussis
Interventions
BIOLOGICAL

Infanrix™ hexa

Intramuscular, three doses

Trial Locations (3)

T5M 3Z7

GSK Investigational Site, Edmonton

V5Z 4H4

GSK Investigational Site, Vancouver

B2N 1L2

GSK Investigational Site, Truro

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY